PD-L1 expression in sebaceous carcinomas

被引：0
作者：
Maelle Saliba
Muhammad Shaheen
Rana El Hajj
Fatmeh Abbas
Shaarif Bashir
Umer Nisar Sheikh
Rami Mahfouz
Asif Loya
Ibrahim Khalifeh
机构：
[1] American University of Beirut Medical Center,Department of Pathology and Laboratory Medicine
[2] Shaukat Khanum Memorial Cancer Hospital and Research Centre,Department of Pathology
来源：
Cancer Immunology, Immunotherapy | 2021年 / 70卷
关键词：
Sebaceous carcinoma; PD-L1; Immunotherapy; Human papilloma virus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1907 / 1915
页数：8
相关论文
共 50 条
  • [41] TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas
    Huanyu Zhang
    Guohui Qin
    Chaoqi Zhang
    Huiyun Yang
    Jinyan Liu
    Hongwei Hu
    Peng Wu
    Shasha Liu
    Li Yang
    Xinfeng Chen
    Xueke Zhao
    Lidong Wang
    Yi Zhang
    Journal of Experimental & Clinical Cancer Research, 40
  • [42] PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature
    Guleria, Prerna
    Kumar, Sunil
    Malik, Prabhat Singh
    Jain, Deepali
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2363 - 2370
  • [43] TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas
    Zhang, Huanyu
    Qin, Guohui
    Zhang, Chaoqi
    Yang, Huiyun
    Liu, Jinyan
    Hu, Hongwei
    Wu, Peng
    Liu, Shasha
    Yang, Li
    Chen, Xinfeng
    Zhao, Xueke
    Wang, Lidong
    Zhang, Yi
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [44] Formin protein DIAPH1 positively regulates PD-L1 expression and predicts the therapeutic response to anti-PD-1/PD-L1 immunotherapy
    Mei, Jie
    Cai, Yun
    Wang, Huiyu
    Xu, Rui
    Zhou, Jiaofeng
    Lu, Jiahui
    Yang, Xuejing
    Pan, Jiadong
    Liu, Chaoying
    Xu, Junying
    Zhu, Yichao
    CLINICAL IMMUNOLOGY, 2023, 246
  • [45] PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
    Madore, Jason
    Vilain, Ricardo E.
    Menzies, Alexander M.
    Kakavand, Hojabr
    Wilmott, James S.
    Hyman, Jessica
    Yearley, Jennifer H.
    Kefford, Richard F.
    Thompson, John F.
    Long, Georgina V.
    Hersey, Peter
    Scolyer, Richard A.
    PIGMENT CELL & MELANOMA RESEARCH, 2015, 28 (03) : 245 - 253
  • [46] PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas
    Perottet, Jeremy
    Le Goff, Emeline
    Legoupil, Delphine
    Quere, Gilles
    Schick, Ulrike
    Marcorelles, Pascale
    Uguen, Arnaud
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2020, 28 (02) : 161 - 165
  • [47] PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm
    Aung, Phyu P.
    Sukswai, Narittee
    Nejati, Reza
    Loghavi, Sanam
    Chen, Weina
    Torres-Cabala, Carlos A.
    Yin, C. Cameron
    Konopleva, Marina
    Zheng, Xiaofeng
    Wang, Jing
    Tang, Zhenya
    Medeiros, L. Jeffrey
    Prieto, Victor G.
    Pemmaraju, Naveen
    Khoury, Joseph D.
    CANCERS, 2019, 11 (05)
  • [48] Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas
    Dilly-Feldis, Marie
    Aladjidi, Nathalie
    Refait, John K.
    Parrens, Marie
    Ducassou, Stephane
    Rullier, Anne
    PEDIATRIC BLOOD & CANCER, 2019, 66 (05)
  • [49] PD-L1 and PD-1 Expression in Early Stage Uterine Endometrioid Carcinoma
    An, Hyo Jung
    Yang, Jung Wook
    Kim, Min Hye
    Song, Dae Hyun
    IN VIVO, 2024, 38 (01): : 246 - 252
  • [50] An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response
    Didem Naz Dioken
    Ibrahim Ozgul
    Irem Yilmazbilek
    Mustafa Cengiz Yakicier
    Ezgi Karaca
    Ayse Elif Erson-Bensan
    Cancer Immunology, Immunotherapy, 2023, 72 : 4065 - 4075
12345